Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment
| Autor: | L Davidson, P Adlard, M Hall, Safa Al-Sarraj, Lisa Cipolotti, Martin N. Rossor, D G O'Donovan, R. J. Cordery |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Paper
Adult Male Pediatrics medicine.medical_specialty Pathology Creutzfeldt-Jakob Syndrome Cerebellum mental disorders Cadaver medicine Humans Dementia Neuropsychological assessment Cognitive decline medicine.diagnostic_test Human Growth Hormone Cognitive disorder Neuropsychology medicine.disease Growth hormone treatment Psychiatry and Mental health Pituitary Gland Female Surgery Neurology (clinical) Cognition Disorders Drug Contamination Psychology Executive dysfunction |
| Zdroj: | Journal of Neurology, Neurosurgery & Psychiatry. 74:1412-1416 |
| ISSN: | 0022-3050 |
| DOI: | 10.1136/jnnp.74.10.1412 |
| Popis: | Background: Most cases of Creutzfeldt-Jakob disease (CJD) in recipients of human cadaveric growth hormone present with a cerebellar syndrome. Dementia is thought to occur late and as a minor feature of the illness. However, neuropsychology data published on these cases are largely qualitative and anecdotal. The first published case does include a neuropsychological assessment seven months after the onset of a cerebellar syndrome, showing evidence of intellectual decline. Subsequent reports hint that cognitive problems may be present in the initial stages of the illness. Objective: To assess early cognition in Creutzfeldt-Jakob disease in recipients of pituitary derived human growth hormone. Methods: Detailed neuropsychology assessment is reported at referral (mean 4.5 months from the onset of symptoms; range 4 to 6 months) in five patients with histologically proven human growth hormone derived CJD. Results: All cases presented with a cerebellar syndrome and only one had noticed mild memory problems. On formal testing, however, four had demonstrable mild intellectual decline, as measured on the WAIS-R. One case showed selective visual memory impairment and frontal executive dysfunction. Conclusions: These findings suggest that, although not the presenting feature, mild cognitive decline may be evident in the early stages of CJD associated with human cadaveric growth hormone treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|